Protalix BioTherapeutics' Q4 2024 Earnings Call: Unraveling Revenue Contradictions and Market Strategies
Monday, Mar 17, 2025 10:26 am ET
1min read These are the key contradictions discussed in Protalix BioTherapeutics' latest 2024Q4 earnings call, specifically including: Revenue Expectations from Elfabrio and Royalty Stream, Market Opportunity for PRX-119, Royalty Revenue Expectations, PRX-115 Market Positioning, and Development Strategy for PRX-115:
Revenue Growth and Diverse Revenue Streams:
- Protalix BioTherapeutics reported revenues from selling goods of $53 million for the year ended December 31, 2024, an increase of 31% compared to the previous year.
- The growth was driven by an increase of $11.8 million in sales to Chiesi, $0.6 million in sales to Brazil, and $0.1 million in sales to Pfizer.
Research and Development Cost Reduction:
- Total research and development expenses decreased by 24% for the year ended December 31, 2024, compared to the previous year.
- This reduction resulted primarily from the completion of the Fabry clinical program and the regulatory process related to the review of the biologic license application and marketing authorization application for Elfabrio.
Strategic Partnership and Intellectual Property Milestones:
- In December 2024, Protalix and Chiesi announced that the European Medicine Agency validated a variation submission for Pegunigalsidase alfa.
- This application was supported by a revised population PK model and a new exposure response analysis, enhancing the IP portfolio and strategic partnership with Chiesi.
Revenue Growth and Diverse Revenue Streams:
- Protalix BioTherapeutics reported revenues from selling goods of $53 million for the year ended December 31, 2024, an increase of 31% compared to the previous year.
- The growth was driven by an increase of $11.8 million in sales to Chiesi, $0.6 million in sales to Brazil, and $0.1 million in sales to Pfizer.
Research and Development Cost Reduction:
- Total research and development expenses decreased by 24% for the year ended December 31, 2024, compared to the previous year.
- This reduction resulted primarily from the completion of the Fabry clinical program and the regulatory process related to the review of the biologic license application and marketing authorization application for Elfabrio.
Strategic Partnership and Intellectual Property Milestones:
- In December 2024, Protalix and Chiesi announced that the European Medicine Agency validated a variation submission for Pegunigalsidase alfa.
- This application was supported by a revised population PK model and a new exposure response analysis, enhancing the IP portfolio and strategic partnership with Chiesi.
Ask Aime: What is the potential impact of Protalix BioTherapeutics' earnings report on stock prices?
Weeks ago I started my trading journey with $1000 and didn’t have much experience. After few days of consistent work and following the recommendations of Elizabeth Towles on Whatsapp +1563 279-8487,I managed to grow my account to $8850
I started my trading journey with minimal knowledge and experience in the cryptocurrency market. I was hesitant and unsure about making investments. However, I came across Catherine E. Russell on Facebook who provided me with expert guidance and training in trading. She shared valuable insights, strategies, and tactics to navigate the volatile market effectively. Her guidance helped me make informed decisions and minimize potential risks, ultimately leading to successful trades and profitable returns. I am grateful to her for her expertise and mentorship.